2.02
+0.18(+9.78%)
Currency In USD
| Previous Close | 1.84 |
| Open | 1.84 |
| Day High | 2.08 |
| Day Low | 1.84 |
| 52-Week High | 47.6 |
| 52-Week Low | 1.52 |
| Volume | 32,691 |
| Average Volume | 718,386 |
| Market Cap | 3.54M |
| PE | -0.07 |
| EPS | -29.03 |
| Moving Average 50 Days | 2.42 |
| Moving Average 200 Days | 5.85 |
| Change | 0.18 |
If you invested $1000 in Indaptus Therapeutics, Inc. (INDP) 10 years ago, it would be worth $0.26 as of February 21, 2026 at a share price of $2.02. Whereas If you bought $1000 worth of Indaptus Therapeutics, Inc. (INDP) shares 5 years ago, it would be worth $3.09 as of February 21, 2026 at a share price of $2.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
GlobeNewswire Inc.
Dec 29, 2025 12:00 PM GMT
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces i
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced t
Indaptus Therapeutics Provides Clinical Update
GlobeNewswire Inc.
Sep 04, 2025 8:01 PM GMT
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSW